A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
What is the purpose of this trial?
The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.
- Ages18 years and older
- Trial withIncyte Corporation
- Start Date02/11/2019
- End Date08/30/2021
- Last Updated02/13/2019
- Study HIC#2000023802